Compound information
- Natural Products
- NACP106239
- Molecular Formula
- C22H32O3
- Molecular Weight
- 344.235144884 g/mol
- Structure
-
- IUPAC Name
- 17-oxodocosa-7,10,13,15,19-pentaenoic acid
- InChI
- InChI=1S/C22H32O3/c1-2-3-15-18-21(23)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(24)25/h3,5-8,11,13,15-16,19H,2,4,9-10,12,14,17-18,20H2,1H3,(H,24,25)
- InChI Key
- PWVSFTLICCBISU-UHFFFAOYSA-N
- SMILES
- O=C(O)CCCCCC=CCC=CCC=CC=CC(=O)CC=CCC
- CAS
- SuperClass
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- SubClass
- Fatty acids and conjugates
- Source
- CNP0346797
Warheads
- Michael Acceptor
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 25 | Ring Count | 0 |
| Heteroatom Count | 3 | Rotatable Bond Count | 15 |
| Hydrogen Bond Acceptor Count | 2 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 54.37 Å2 | LogP | 5.947 |
| LogS | -5.747 | LogD | 3.835 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.984 | Pgp substrate | 0.0 |
| HIA | 0.967 | F20 % | 0.992 |
| F30 % | 0.668 | Caco-2 | -4.795 |
| MDCK | -4.45 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.652 | PPB | 82.9 |
| VD | 0.725 | Fu | 1.904 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.595 | CYP1A2 substrate | 0.309 |
| CYP2A6 substrate | 0.34 | CYP2B6 substrate | 0.367 |
| CYP2C19 inhibitor | 0.052 | CYP2C19 substrate | 0.349 |
| CYP2C8 substrate | 0.503 | CYP2C9 inhibitor | 0.812 |
| CYP2C9 substrate | 0.035 | CYP2D6 inhibitor | 0.088 |
| CYP2D6 substrate | 0.252 | CYP2E1 substrate | 0.213 |
| CYP3A4 inhibitor | 0.08 | CYP3A4 substrate | 0.016 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.92 | CL | 4.297 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.947 | Hepatotoxicity | 0.9 |
| Mutagenicity | 0.58 | Rat Oral Acute Toxicity | 0.005 |
| FDAMDD | 0.382 | Skin Sensitization | 0.973 |
| Carcinogenicity | 0.886 | Eye Corrosion | 0.884 |
| Eye Irritation | 0.942 | Respiratory Toxicity | 0.839 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 0.743 | IGC50 | 4.103 |
| LC50FM | 5.794 | LC50DM | 6.376 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.336 | NR-AR-LBD | 0.503 |
| NR-AhR | 0.004 | NR-Aromatase | 0.071 |
| NR-ER | 0.322 | NR-ER-LBD | 0.318 |
| NR-PPAR-gamma | 0.878 | SR-ARE | 0.926 |
| SR-ATAD5 | 0.346 | SR-HSE | 0.83 |
| SR-MMP | 0.045 | SR-p53 | 0.684 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.